The Rise of Multimodal R&D and AI in Driving Pharma Innovation
The ebook "The Rise of Multimodal R&D and AI in Driving Pharma Innovation" explains how Dotmatics' Luma platform integrates diverse scientific data and leverages AI to overcome challenges like high costs and data silos, enabling pharmaceutical and biotech companies to accelerate drug discovery, enhance collaboration, and prepare for an AI-driven future in research and development.
Unlock the Future of Pharma Innovation: Multimodal R&D and AI
Read this ebook to discover how Dotmatics' Luma platform supports cutting-edge research by bringing together different scientific disciplines and preparing for an AI-driven future. It discusses the challenges pharma companies face, such as increasing costs and the need for better collaboration, and shows how a flexible, data-driven platform like Luma can help streamline workflows and eliminate data silos.
In this ebook, we review recent trends seen with AI in the pharmaceutical industry and explore how companies can best position themselves to ensure their R&D data are AI-ready.
Discover how top pharma and biotech companies are driving breakthroughs with the power of multimodal research and AI. Our latest ebook, "The Rise of Multimodal R&D and AI in Driving Pharma Innovation," explores how to transform your R&D processes, accelerate drug discovery, and prepare for an AI-enabled future.
What you'll learn:
- Why multimodal R&D is crucial for staying ahead in today's competitive landscape
- How integrating data from diverse scientific disciplines can speed up innovation
- The role of AI in reducing costs, enhancing collaboration, and improving decision-making
- How Dotmatics' Luma platform is empowering teams to break down data silos and streamline workflows
Who should read this: This ebook is perfect for R&D leaders, scientists, and decision-makers in the pharmaceutical and biotech industries who are ready to embrace the next generation of research technology.
Related
Data Evolution in Pharma: The Spread of Multimodal
The pharmaceutical industry is shifting from single-mode to multimodal drug discovery, incorporating diverse therapeutic modalities like biologics, gene therapies, and small molecules, but this evolution presents significant challenges in integrating heterogeneous R&D data and technologies, necessitating advanced, compatible platforms to enable efficient collaboration and leverage AI-driven insights for faster, cost-effective drug development.
3 Customer Trends We’re Watching in 2025
In 2025, life science teams are prioritizing three key trends—Lab-in-a-Loop platforms that integrate instruments, data, workflows, and models to boost R&D efficiency; true multimodal discovery enabled by flexible informatics supporting diverse data types without fragmented tools; and Composite AI leveraging layered, governed, and traceable data across disciplines—all aimed at delivering tangible scientific innovation while addressing resource constraints and stringent AI governance requirements.
Limitations of Existing Life Science Software—and the Opportunity to Evolve
Existing life science software tools like ELNs, LIMS, and SDMS, while essential for digitizing workflows and managing data, are limited by their siloed, non-real-time, and non-AI-integrated designs, presenting an opportunity to evolve by integrating them into unified, intelligent platforms—such as Dotmatics Luma—that enable connected, workflow-aware, multimodal scientific intelligence with adaptive workflows, real-time data flow, and cross-functional insights without replacing core systems.
How Luma Lab Connect Automates Lab Data Acquisition Across 100+ Instruments
Dotmatics Luma Lab Connect, part of the Dotmatics Luma multimodal scientific R&D platform, automates and streamlines the acquisition, management, and preparation of complex, multimodal lab data from over 100 diverse instruments and sources, addressing challenges of data security, integrity, and usability to enhance research productivity and enable FAIR data practices within a unified, low-code SaaS environment.
From Foundational to Aspirational: Dotmatics CEO on the Three Phases of R&D Digital Transformation
Dotmatics CEO outlines the accelerating digital transformation in life sciences R&D driven by exploding data volumes, emphasizing the shift towards AI and machine learning despite unique industry challenges such as lack of standardized interoperability and a fragmented ecosystem, which complicate progress toward a predictive, generative AI-enabled future in drug discovery.
Maximize Your Data Impact
The article discusses how R&D leaders can maximize the impact of their data by adopting AI/ML technologies, establishing robust data infrastructures, and leveraging automation and external partnerships, as highlighted by insights from Dotmatics' collaboration with LINUS and their State of Science survey revealing scientists' strategic shifts toward automation and partnerships amid scientific and economic challenges.